{"id":100248,"date":"2012-01-11T15:02:06","date_gmt":"2012-01-11T15:02:06","guid":{"rendered":"https:\/\/knome.com\/?p=100248"},"modified":"2024-09-12T15:06:02","modified_gmt":"2024-09-12T15:06:02","slug":"knome-names-new-ceo-cuts-deal-with-johns-hopkins-to-analyze-1000-genomes","status":"publish","type":"post","link":"https:\/\/www.knome.com\/?p=100248","title":{"rendered":"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;section&#8221; _builder_version=&#8221;4.27.0&#8243; custom_margin=&#8221;0px||0px||false|false&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_row admin_label=&#8221;row&#8221; _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221; theme_builder_area=&#8221;post_content&#8221;][et_pb_heading title=&#8221;Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes&#8221; _builder_version=&#8221;4.27.0&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#E02B20&#8243; title_font_size=&#8221;25px&#8221; custom_margin=&#8221;0px||0px||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;][\/et_pb_heading][et_pb_text admin_label=&#8221;Text&#8221; _builder_version=&#8221;4.27.0&#8243; text_font_size=&#8221;14px&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; hover_enabled=&#8221;0&#8243; global_colors_info=&#8221;{}&#8221; theme_builder_area=&#8221;post_content&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><strong><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg\" width=\"193\" height=\"194\" alt=\"\" class=\"wp-image-100213 alignnone size-full\" style=\"float: left;\" srcset=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg 249w, https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s-150x150.jpg 150w\" sizes=\"(max-width: 193px) 100vw, 193px\" \/>Luke Timmerman of Xconomy covers Knome\u2019s announcement of a new CEO and signing of la<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><strong>rge deal with Johns Hopkins.<\/strong><br \/><span>Excerpt: Like a\u00a0lot of biotech executives focused on developing drugs, Martin Tolar has long been skeptical of the value of genomics in bringing about personalized medicine. But over the past few months of scoping out new opportunities, he\u2019s become enough of a\u00a0believer to jump into genomics with both feet, as the new CEO of Cambridge, MA-based Knome.<\/span><\/p>\n<p>\u201cYou always hear about genomics and the revolution that never happened,\u201d Tolar says. \u201cThere was Millennium and deCode, and others who raised lots of money. But I\u00a0looked at this and said, \u2018No, this is incredible, it\u2019s really happening.\u2019 All the pieces of equation are coming\u00a0together.\u2019\u201d<\/p>\n<p>Tolar, the former CEO of Wellesley, MA-based NormOxys, is joining Knome just as it has completed its fourth year in business, which was by far its best. The company is announcing today that it has won a\u00a0new contract to analyze and compare 1,000 genomes for scientists at Johns Hopkins University, who are looking for genetic variants linked to asthma in African American and African Caribbean populations. It\u2019s the latest addition to Knome\u2019s roster of about 100 customers for its genomic-analysis software service, although the Hopkins project is by far the biggest. Knome isn\u2019t disclosing the value of the new project, but the company expects to generate $20 million in revenue in 2012 from academic, biotech, and pharmaceutical industry customers, Tolar\u00a0says\u2013<a href=\"http:\/\/www.xconomy.com\/boston\/2012\/01\/09\/knome-names-new-ceo-cuts-deal-with-johns-hopkins-to-analyze-1000-genomes\/\" target=\"_blank\" rel=\"noopener\">read the full article<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Luke Timmerman of Xconomy covers Knome\u2019s announcement of a new CEO and signing of la &nbsp; rge deal with Johns Hopkins.Excerpt: Like a\u00a0lot of biotech executives focused on developing drugs, Martin Tolar has long been skeptical of the value of genomics in bringing about personalized medicine. But over the past few months of scoping out [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":100213,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<img class=\"size-full wp-image-100015 alignleft\" src=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/GENALICE.jpg\" alt=\"\" width=\"300\" height=\"70\" \/>\r\n\r\nHARDERWIJK, the Netherlands and CAMBRIDGE, Mass \u2013 January 12, 2015 \u2013 Today GENALICE and Knome, Inc. USA jointly announced a strategic partnership to offer their products together as a turn-key solution for those using next-generation sequencing (NGS) data to interpret patients\u2019 genomes. GENALICE MAP is an ultra-fast and highly accurate preprocessing solution for aligning and calling NGS data and seamlessly connects to Knome\u2019s informatics and genomics interpretation system, the knoSYS<sup>\u00ae<\/sup>\u00a0platform.\r\n\r\nStated CEO and President of Knome, Wolfgang Daum, \u201cThe GENALICE and Knome partnership came about in response to the reality that the amount of NGS data and its increasing usage requires processing and interpreting at an incredible pace. Wide-spread implementation of sequencing in the clinic toward the goal of precision medicine will only make this fact more apparent.\u201d\r\n\r\nWhile both products will continue to be offered separately, customers wanting to take advantage of the combined system can expect a reduction of NGS data bottlenecks, improved ability to annotate and interpret human genomes, and unprecedented control over their data from end-to-end.\r\n\r\nHans Karten, CEO of GENALICE, commented, \u201cWhereas GENALICE MAP speeds up and improves the process of aligning and calling genomes, the knoSYS platform focuses on the annotation and interpretation piece. These two products complement each other beautifully in creating a workflow that eliminates many of the frustrations of wrangling NGS data today.\u201d\r\n\r\n<strong>About Knome, Inc.<\/strong>\r\nKnome, Inc. is a leading provider of human genome interpretation systems and services. Knome provides tools and solutions that help researchers, drug developers, and clinicians determine the genetic basis of human disease and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome\u2019s big data technologies are helping to smooth the healthcare industry\u2019s transition to molecular-based, precision medicine.\r\n\r\n<strong>About GENALICE<\/strong>\r\nGENALICE is a highly innovative biomedical big data company, with global headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis on general-purpose hardware. With GENALICE MAP, it introduced the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome and exome sequencing for biomarker discovery and medical application. More information on GENALICE can be found at\u00a0<a href=\"http:\/\/www.genalice.com\/\" target=\"_blank\" rel=\"noopener\">www.genalice.com<\/a>.\r\n\r\n<strong>Media Contacts<\/strong>\r\n<div>Knome, Inc. USA\r\nJessica Vionas\r\nDirector of Marketing\r\n617-715-1000 x2012\r\njvionas@knome.com<\/div>\r\n<div>GENALICE B.V.\r\nJos Lunenberg\r\nChief Business Officer\r\n+31 88 1221 000\r\njos.lunenberg@genalice.com<\/div>\r\n<p align=\"center\">###<\/p>\r\n<p align=\"center\"><\/p>","_et_gb_content_width":"","footnotes":""},"categories":[15],"tags":[],"class_list":["post-100248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-in-the-media"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes - Knome<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.knome.com\/?p=100248\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes - Knome\" \/>\n<meta property=\"og:description\" content=\"Luke Timmerman of Xconomy covers Knome\u2019s announcement of a new CEO and signing of la &nbsp; rge deal with Johns Hopkins.Excerpt: Like a\u00a0lot of biotech executives focused on developing drugs, Martin Tolar has long been skeptical of the value of genomics in bringing about personalized medicine. But over the past few months of scoping out [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.knome.com\/?p=100248\" \/>\n<meta property=\"og:site_name\" content=\"Knome | Genome Interpretation Systems &amp; Services\" \/>\n<meta property=\"article:published_time\" content=\"2012-01-11T15:02:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-12T15:06:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"249\" \/>\n\t<meta property=\"og:image:height\" content=\"250\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jason Bailey\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jason Bailey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248\"},\"author\":{\"name\":\"Jason Bailey\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/#\\\/schema\\\/person\\\/eb7b08ce3aec9801f4fc316c4122bed3\"},\"headline\":\"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes\",\"datePublished\":\"2012-01-11T15:02:06+00:00\",\"dateModified\":\"2024-09-12T15:06:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248\"},\"wordCount\":445,\"image\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg\",\"articleSection\":[\"In The Media\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248\",\"url\":\"https:\\\/\\\/www.knome.com\\\/?p=100248\",\"name\":\"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes - Knome\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg\",\"datePublished\":\"2012-01-11T15:02:06+00:00\",\"dateModified\":\"2024-09-12T15:06:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/#\\\/schema\\\/person\\\/eb7b08ce3aec9801f4fc316c4122bed3\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.knome.com\\\/?p=100248\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248#primaryimage\",\"url\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg\",\"contentUrl\":\"https:\\\/\\\/www.knome.com\\\/wp-content\\\/uploads\\\/2024\\\/09\\\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg\",\"width\":249,\"height\":250},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/?p=100248#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.knome.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/#website\",\"url\":\"https:\\\/\\\/www.knome.com\\\/\",\"name\":\"Knome | Genome Interpretation Systems &amp; Services\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.knome.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.knome.com\\\/#\\\/schema\\\/person\\\/eb7b08ce3aec9801f4fc316c4122bed3\",\"name\":\"Jason Bailey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x\",\"caption\":\"Jason Bailey\"},\"url\":\"https:\\\/\\\/www.knome.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes - Knome","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.knome.com\/?p=100248","og_locale":"en_US","og_type":"article","og_title":"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes - Knome","og_description":"Luke Timmerman of Xconomy covers Knome\u2019s announcement of a new CEO and signing of la &nbsp; rge deal with Johns Hopkins.Excerpt: Like a\u00a0lot of biotech executives focused on developing drugs, Martin Tolar has long been skeptical of the value of genomics in bringing about personalized medicine. But over the past few months of scoping out [&hellip;]","og_url":"https:\/\/www.knome.com\/?p=100248","og_site_name":"Knome | Genome Interpretation Systems &amp; Services","article_published_time":"2012-01-11T15:02:06+00:00","article_modified_time":"2024-09-12T15:06:02+00:00","og_image":[{"width":249,"height":250,"url":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg","type":"image\/jpeg"}],"author":"Jason Bailey","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jason Bailey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.knome.com\/?p=100248#article","isPartOf":{"@id":"https:\/\/www.knome.com\/?p=100248"},"author":{"name":"Jason Bailey","@id":"https:\/\/www.knome.com\/#\/schema\/person\/eb7b08ce3aec9801f4fc316c4122bed3"},"headline":"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes","datePublished":"2012-01-11T15:02:06+00:00","dateModified":"2024-09-12T15:06:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.knome.com\/?p=100248"},"wordCount":445,"image":{"@id":"https:\/\/www.knome.com\/?p=100248#primaryimage"},"thumbnailUrl":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg","articleSection":["In The Media"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.knome.com\/?p=100248","url":"https:\/\/www.knome.com\/?p=100248","name":"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes - Knome","isPartOf":{"@id":"https:\/\/www.knome.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.knome.com\/?p=100248#primaryimage"},"image":{"@id":"https:\/\/www.knome.com\/?p=100248#primaryimage"},"thumbnailUrl":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg","datePublished":"2012-01-11T15:02:06+00:00","dateModified":"2024-09-12T15:06:02+00:00","author":{"@id":"https:\/\/www.knome.com\/#\/schema\/person\/eb7b08ce3aec9801f4fc316c4122bed3"},"breadcrumb":{"@id":"https:\/\/www.knome.com\/?p=100248#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.knome.com\/?p=100248"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.knome.com\/?p=100248#primaryimage","url":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg","contentUrl":"https:\/\/www.knome.com\/wp-content\/uploads\/2024\/09\/xconomyFeature-2we28ic1viyddsjp5um41s.jpg","width":249,"height":250},{"@type":"BreadcrumbList","@id":"https:\/\/www.knome.com\/?p=100248#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.knome.com\/"},{"@type":"ListItem","position":2,"name":"Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes"}]},{"@type":"WebSite","@id":"https:\/\/www.knome.com\/#website","url":"https:\/\/www.knome.com\/","name":"Knome | Genome Interpretation Systems &amp; Services","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.knome.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.knome.com\/#\/schema\/person\/eb7b08ce3aec9801f4fc316c4122bed3","name":"Jason Bailey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x","url":"https:\/\/secure.gravatar.com\/avatar\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/56bce6b92ef218a6b47a057c253c7c75450a6bb5a6b3e61df84aa47d5443f933?s=96&d=wavatar&r=x","caption":"Jason Bailey"},"url":"https:\/\/www.knome.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts\/100248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=100248"}],"version-history":[{"count":4,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts\/100248\/revisions"}],"predecessor-version":[{"id":100252,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/posts\/100248\/revisions\/100252"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=\/wp\/v2\/media\/100213"}],"wp:attachment":[{"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=100248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=100248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.knome.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=100248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}